{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260528295148/en/Bristol-Myers-Squibb-Announces-CELMoD-Mezigdomide-Reduces-Risk-of-Disease-Progression-or-Death-by-More-than-50-vs.-Standard-of-Care-in-Relapsed-or-Refractory-Multiple-Myeloma", "message": "News view counter 766690 successfully enlarged"}